Skip to main content
Premium Trial:

Request an Annual Quote

Angsana Cancer Fusion Panel Selected for Ignyta Clinical Trial

NEW YORK (GenomeWeb) – Angsana Molecular & Diagnostics has announced a partnership with Ignyta on screening for a cancer therapy clinical trial being conducted in Asia.

Under the terms of the agreement, Angsana will provide cancer screening using its RNA-based cancer panel to detect TRK, ROS1, and ALK fusions in patients participating in the STARTRK-2 Phase 2 basket trial for entrectinib, a tyrosine kinase inhibitor. The firm will support the trial from its CAP-accredited labs in Singapore and Hong Kong.

"Entrectinib is the only TRK inhibitor to have published data demonstrating [treatment responses] in non-small cell lung cancer and in patients with cancer in the central nervous system," Ignyta CEO Jonathan Lim said in a statement. "The anti-tumor activity seen across cancer types and entrectinib's ability to treat bulky CNS disease — particularly important given the propensity for many solid tumors to metastasize to the brain — is extremely encouraging."

In November, Angsana signed a deal with Euroimmun for allergy testing Southeast Asia.